VOLITIONRX LTD VNRX
Last close
0.17
2026-10-23
Market cap
$2.4M
2026-06-30 share count
52-week range
0.16 - 9.50
Valuation FY2025 figures against the last close
P/S1.4x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.2M | $775.3K | $306.4K | $90.0K | $13.4K | $17.1K | — | — | — |
| R&D | $10.1M | $14.4M | $19.6M | $15.3M | $13.0M | $14.5M | $10.4M | $10.9M | $8.0M | $7.9M |
| SG&A | $9.5M | $8.5M | $10.4M | $10.2M | $11.7M | $5.7M | $4.7M | $5.8M | $5.8M | $4.2M |
| Total operating expenses | $23.5M | $28.3M | $36.8M | $32.1M | $28.4M | $21.3M | $16.1M | $17.9M | $14.7M | $12.4M |
| Operating income | -$21.7M | -$27.0M | -$36.0M | -$31.8M | -$28.3M | -$21.2M | -$16.0M | -$17.9M | -$14.7M | -$12.4M |
| Interest expense | — | — | — | — | $155.8K | $129.8K | $126.6K | $110.9K | $73.1K | $20.4K |
| Net income | -$23.4M | -$27.0M | -$35.7M | -$30.6M | -$27.0M | -$20.4M | -$16.1M | -$18.0M | -$14.8M | -$11.9M |
| EPS, diluted | — | -0.31 | -0.50 | — | -0.51 | -0.45 | -0.41 | -0.57 | -0.56 | -0.52 |
| Shares, diluted (wtd. avg.) | 106.8M | 86.5M | 71.2M | — | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.1M | $3.3M | $20.7M | $10.9M | $20.6M | $19.4M | $17.0M | $13.4M | $10.1M | $21.7M |
| Receivables | $317.8K | $110.6K | $242.6K | $72.6K | $12.5K | $7.1K | $0 | — | — | — |
| Total current assets | $2.1M | $4.1M | $21.9M | $12.2M | $22.0M | $20.3M | $17.6M | $13.9M | $10.6M | $22.0M |
| Property, plant and equipment | $4.0M | $4.4M | $5.5M | $5.4M | $4.9M | $5.2M | $3.0M | $3.1M | $3.5M | $2.1M |
| Other intangibles | $316.7K | $313.7K | $23.9K | $110.5K | $216.9K | $321.6K | $372.3K | $466.9K | $576.4K | $602.2K |
| Total assets | $6.9M | $9.4M | $28.0M | $18.3M | $27.5M | $26.2M | $21.3M | $17.5M | $14.6M | $24.7M |
| Accounts payable | $2.9M | $2.8M | $3.2M | $3.0M | $1.5M | $1.5M | $627.3K | $807.2K | $351.7K | $281.2K |
| Short-term debt | $890.6K | $860.2K | $1.2M | $1.1M | $797.9K | $841.3K | $647.6K | $416.6K | $443.9K | $30.7K |
| Total current liabilities | $12.2M | $7.8M | $8.9M | $17.4M | $6.5M | $6.2M | $3.9M | $2.3M | $2.3M | $2.0M |
| Long-term debt | $5.8M | $4.0M | $3.6M | $2.8M | $2.3M | $2.6M | $2.2M | $2.0M | $1.3M | $432.0K |
| Total liabilities | $42.5M | $35.5M | $36.7M | $21.4M | $9.8M | $9.9M | $7.1M | $5.3M | $4.7M | $3.6M |
| Retained earnings | -$252.9M | -$229.5M | -$202.6M | -$167.3M | -$137.0M | -$110.2M | -$89.8M | -$73.7M | -$55.7M | -$40.9M |
| Total equity | -$34.2M | -$24.9M | -$8.7M | -$3.1M | $17.7M | $16.3M | $14.2M | $12.1M | $10.0M | $21.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.7M | -$25.9M | -$18.1M | -$15.3M | -$20.9M | -$16.5M | -$12.7M | -$14.7M | -$12.2M | -$8.9M |
| Depreciation and amortisation | $1.0M | $1.1M | $1.1M | $865.3K | $812.1K | $627.6K | $589.5K | $548.0K | $454.5K | $222.9K |
| Stock-based compensation | $1.7M | $1.3M | $2.3M | $3.1M | $2.5M | — | $1.5M | $2.6M | $2.4M | $1.7M |
| Capital expenditure | $89.6K | $277.5K | $1.1M | $1.6M | $973.6K | $1.9M | $511.3K | $301.8K | $1.4M | $415.1K |
| Investing cash flow | -$89.6K | -$573.9K | -$1.1M | -$1.6M | -$973.6K | -$1.6M | -$511.3K | -$301.8K | -$1.4M | -$415.1K |
| Financing cash flow | $17.1M | $8.7M | $29.0M | $6.9M | $22.9M | $20.6M | $16.9M | $18.0M | $2.0M | $25.2M |
| Buybacks | — | $0 | $31.8K | $0 | — | $54.4K | $0 | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001477932-26-002685.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $17.1K | $13.4K | $90.0K | $306.4K | $775.3K | $1.2M | $1.7M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$11.9M | -$14.8M | -$18.0M | -$16.1M | -$20.4M | -$27.0M | -$30.6M | -$35.7M | -$27.0M | -$23.4M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Unregistered share sale Item 3.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Unregistered share sale Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Unregistered share sale Item 3.02
- Material agreement signed Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.51B | 29.3x | 0.5% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| NTLA | Intellia Therapeutics, Inc. | $1.57B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $667.8M | — | — |
| MYGN | MYRIAD GENETICS INC | $556.7M | — | -1.6% |